Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases
Insilico Medicine (HKG: 3696) and South Korea’s SK Biopharmaceuticals announced a strategic collaboration leveraging artificial...